HC Wainwright reaffirmed their neutral rating on shares of Lyell Immunopharma (NASDAQ:LYEL - Free Report) in a research note published on Thursday,Benzinga reports. They currently have a $1.00 target price on the stock.
Lyell Immunopharma Stock Down 3.4 %
Shares of NASDAQ LYEL traded down $0.02 during trading hours on Thursday, hitting $0.59. 1,017,025 shares of the stock were exchanged, compared to its average volume of 1,042,534. The company has a market cap of $171.03 million, a PE ratio of -0.74 and a beta of -0.41. The firm has a fifty day moving average price of $0.62 and a 200-day moving average price of $0.92. Lyell Immunopharma has a 12 month low of $0.51 and a 12 month high of $3.15.
Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last released its earnings results on Wednesday, March 12th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.52). The company had revenue of $0.01 million for the quarter. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. As a group, equities analysts anticipate that Lyell Immunopharma will post -0.78 earnings per share for the current fiscal year.
Institutional Trading of Lyell Immunopharma
Several large investors have recently bought and sold shares of the stock. Decheng Capital LLC purchased a new stake in shares of Lyell Immunopharma in the 4th quarter valued at $7,622,000. Foresite Capital Management V LLC purchased a new stake in shares of Lyell Immunopharma in the 4th quarter valued at $5,205,000. venBio Partners LLC purchased a new stake in shares of Lyell Immunopharma in the 4th quarter valued at $4,545,000. Renaissance Technologies LLC boosted its holdings in shares of Lyell Immunopharma by 716.7% in the 4th quarter. Renaissance Technologies LLC now owns 1,612,146 shares of the company's stock valued at $1,032,000 after acquiring an additional 1,414,746 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in Lyell Immunopharma during the fourth quarter worth $887,000. Hedge funds and other institutional investors own 66.05% of the company's stock.
About Lyell Immunopharma
(
Get Free Report)
Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.
Featured Articles
Before you consider Lyell Immunopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lyell Immunopharma wasn't on the list.
While Lyell Immunopharma currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
